PeptidePedia The community reference

Prior authorisation (revision 4)

Old revision·06:16, 6 Jan 2025·DisparityDagny

This is an old revision of this page, as it stood at 06:16, 6 Jan 2025, saved by DisparityDagny with the summary fix a dangling clause. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Prior authorisation
Also calledPre-authorisation, pre-approval
Decided byThe payer, not the prescriber
Common criteriaBody-mass index, comorbidity, prior therapy
Topic infobox · conventions

Prior authorisation is a requirement imposed by a payer that a prescription be approved before it will be covered. It is a coverage mechanism rather than a clinical one, and the decision is made by the payer against its own criteria.[1]

For incretin therapies it is close to universal where these drugs are covered at all, and the criteria commonly include a body-mass index threshold, a comorbidity, documented prior attempts at other management, and sometimes a requirement to try a specified alternative first.[1]

How it operates

[edit]

A prescriber submits a request with supporting documentation; the payer assesses it against published or unpublished criteria; approval, denial, or a request for further information follows. Denials may be appealed, in a process with its own timelines.[2]

Step therapy — a requirement to have tried and failed a specified alternative — is a common form. Its rationale is cost containment; its cost is delay and, where the specified alternative is less effective, a period of less effective treatment.[1]

References

  1. ^ a b c American Diabetes Association. "Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).
  2. ^ Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." Nursing Clinics of North America 56(4):635–645 (2021). PMID 34749900.